Compared to warfarin, both dabigatran and FXa inhibitors similarly reduced the risk of stroke: RR 0.86, 95% CI 0.65–1.14 and RR 0.89, 95% CI 0.76–1.04, respectively. This evidence concerns the gene F10 and stroke disorder.